Mergers and Acquisitions Archives - Kybora

首页
关于我们
我们的服务
最新发布
联系我们
中文
- English
- 中文

首页
关于我们
我们的服务
最新发布
联系我们
中文
- English
- 中文

KYBORA is pleased to announce that its client Bayer Healthcare Pharmaceuticals has sold a Priority Review Voucher (PRV) to argenx.

11月 23, 2020

No comments

Mergers and Acquisitions, News

KYBORA is pleased to announce that its client Bayer Healthcare Pharmaceuticals has sold a Priority Review Voucher (PRV) to argenx.

Recent blog post.

The Impact of the Inflation Reduction Act (IRA) on Orphan Drugs

Posted: 2月 ago
Competition in the Biotech Industry

Posted: 3月 ago
Navigating the Complexities of Market Access and Reimbursement in the US Biotech Industry

Posted: 3月 ago
Navigating Biotech Product Licensing in China: Bridging Opportunity and Complexity

Posted: 3月 ago
Navigating the Complex Intellectual Property Landscape as a Biotech CEO

Posted: 4月 ago

Tags.

#biopharma Licensing Announcement Bausch Health biopharma biotechnology China Conference Corporate globalhealthcare healthtech Kybora Team LIcensing March 2020 mergersandacquisitions News Priority List Stada license

我们期待听取您关于业务拓展的需求

KYBORA是一家聚焦创新医药和医疗器械领域的全球化顾问公司。她以帮助客户拓展全球业务并取得卓越业绩为使命，为遍布世界各地的客户提供包括全球产权交易、融资、收并购、资源对接及高端战略咨询在内的优质服务。

关于我们.

关于开博锐
核心团队
成功案例
全球驻地

我们的服务.

收并购
产权交易
融资
战略咨询

最新发布.

The Impact of the Inflation Reduction Act (IRA) on Orphan Drugs

Posted: 2月 ago
Competition in the Biotech Industry

Posted: 3月 ago

© KYBORA All Rights Reserved.

Terms of service | Privacy policy

TYPE & ENTER: